

EDITORIAL

Open Access



Standard: Human intestinal organoids

Yalong Wang^{1,2,3,4†}, Hanqing Lin^{5†}, Lianzheng Zhao^{1†}, Fan Hong^{2†}, Jie Hao^{6,7,8,9}, Zhen Zhang^{10,11,12}, Weiqi Sheng^{11,13}, Linhong Song¹⁴, Chu-Xia Deng¹⁵, Bing Zhao¹⁶, Jiani Cao^{6,7,8,9}, Lei Wang^{6,7,8,9}, Liu Wang^{6,7,8,9}, Lingmin Liang^{6,7,8,9}, Wenli Kelly Chen¹⁷, Chunping Yu¹⁸, Zhijian Sun¹⁹, Yingying Yang²⁰, Changlin Wang^{21,9}, Yong Zhang^{22,23}, Qiyuan Li^{24,9}, Ka Li^{22,9}, Aijin Ma^{25,9*}, Tongbiao Zhao^{6,7,8,9*}, Guoqiang Hua^{10,5*} and Ye-Guang Chen^{1,2,26*}

Abstract

Organoids have attracted great interest for disease modelling, drug discovery and development, and tissue growth and homeostasis investigations. However, lack of standards for quality control has become a prominent obstacle to limit their translation into clinic and other applications. “Human intestinal organoids” is the first guideline on human intestinal organoids in China, jointly drafted and agreed by the experts from the Chinese Society for Cell Biology and its branch society: the Chinese Society for Stem Cell Research. This standard specifies terms and definitions, technical requirements, test methods, inspection rules for human intestinal organoids, which is applicable to quality control during the process of manufacturing and testing of human intestinal organoids. It was originally released by the Chinese Society for Cell Biology on 24 September 2022. We hope that the publication of this standard will guide institutional establishment, acceptance and execution of proper practical protocols and accelerate the international standardization of human intestinal organoids for applications.

[†]Yalong Wang, Hanqing Lin, Lianzheng Zhao and Fan Hong contributed equally to this work.

*Correspondence:

Aijin Ma
783869855@qq.com
Tongbiao Zhao
tbzhao@ioz.ac.cn
Guoqiang Hua
guoqianghua@fudan.edu.cn
Ye-Guang Chen
ygchen@tsinghua.edu.cn

Full list of author information is available at the end of the article

Scope

This document specifies the ethical requirements, technical requirements, and testing methods for human intestinal organoids.

This standard applies to the production and testing of human intestinal organoids.

Normative references

The following referenced documents are indispensable for the application of these documents. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including all amendments) applies.

WS 213 Diagnosis for Hepatitis C
 WS 293 Diagnostic Criteria for HIV/AIDS
 WS 299 Diagnostic Criteria for Viral Hepatitis B
 Pharmacopoeia of the People's Republic of China (2020 Edition)
 National Guide to Clinical Laboratory Procedures

Terms and definitions

The following terms and definitions apply to this document.

Organoids

Three-dimensional (3D) structures that grow from stem cells or progenitor cells *in vitro*, consist of organ-specific cell types, and can mimic the *in vivo* architecture and specific function of the original tissue (Clevers 2016; Fujii and Sato 2021; Kim et al. 2020; Sato et al. 2009).

Human intestinal organoids

Organoids that develop from human intestinal stem cells of normal tissue, which are capable of self-formation, long-term growth and renewal, and possess a variety of mature intestinal epithelial cell types (Sato and Clevers 2013; Sato et al. 2011a).

Passage

Process of dissociating existing organoids into smaller fragments, or single cell via physical, chemical, or biological methods, and keeping them growing *in vitro* under the same culture conditions (Ganesh et al. 2019).

Cryopreservation

Freezing process by which organoids are maintained at low temperature in an inactive state for maintaining

cellular composition, gene expression, and functional properties.

Thawing

Process of bringing frozen organoids from an inactive to an actively growing state.

Intestinal stem cells

Cells that can self-renew and possess the ability to differentiate into all types of intestinal epithelial cells (Barker 2014; Barker et al. 2012; Beumer and Clevers 2021; Gehart and Clevers 2019).

Intestinal stem cell differentiation

Process of intestinal stem cells dividing into their daughter cells, including enterocytes, goblet cells, Paneth cells, enteroendocrine cells, et al. (Beumer and Clevers 2021; Gehart and Clevers 2019).

Transit amplifying cells (TA cells)

Cells that are initially expanded from stem cells and have high proliferative capacity, and can initially differentiate into progenitor cells and further differentiate into various types of mature intestinal epithelial cells (Beumer and Clevers 2021; Gehart and Clevers 2019).

Enterocytes

Intestinal epithelial cells that are mainly responsible for the absorption of nutrients from the intestinal lumen, which are columnar with oval nuclei located at the base of the cells and with regularly arranged microvilli located at the luminal side (Beumer and Clevers 2021; Gehart and Clevers 2019).

Goblet cells

Intestinal epithelial cells that secrete mucus periodically, which are enlarged and cup-shaped with the filled mucus particles at the top and the nucleus at the bottom (Beumer and Clevers 2021; Gehart and Clevers 2019; Gustafsson and Johansson 2022).

Paneth cells

Intestinal epithelial cells that usually gather at the bottom of the small intestinal crypts and intermingle with intestinal stem cells, which are conical in shape with thick eosinophilic secretory granules on the top and the round nucleus at the base (Beumer and Clevers 2021; Bevins and Salzman 2011; Clevers 2013; Gehart and Clevers 2019; Porter et al. 2002).

Enteroendocrine cells

Intestinal epithelial cells that secrete intestinal hormones in response to luminal food stimulation or pH

changes, which are irregularly conical with a large number of secretory particles at the bottom (Beumer and Clevers 2021; Gehart and Clevers 2019; Gribble and Reimann 2019).

Ethics requirements

A legal and valid informed consent shall be signed by the donor who provides the tissue to develop the organoid. The consent form includes, but not limited to, potential research and therapeutic applications under the appropriate conditions, potential commercial applications of research results, and other issues applicable.

The production and research project of human intestinal cancer organoids shall be approved by the ethics review committee.

The personal information of donors shall be protected.

Technical requirements

Morphology

Human intestinal organoids shall be cystic or bud-like, with a cavity in the middle and tightly contacting columnar epithelial cells on the outside under optical microscopy. The cavities and the edges of the junctions shall be clear, and the cells shall be transparent (Sato et al. 2011a; Wang et al. 2022a).

Chromosomal karyotype

The chromosomal karyotype of human intestinal organoids shall be 46, XY or 46, XX.

Marker genes

Marker gene expressions shall be detected in human intestinal organoids, including the stem cell marker *LGR5* (Barker et al. 2007), the goblet cell marker *MUC2* (Chang et al. 1994), the enterocyte marker *ALPI* (Tetteh et al. 2016), the enteroendocrine cell marker *CHGA* (Zeve et al. 2022), and the proliferative cell marker *MKI67* (Beumer and Clevers 2021). In addition, the Paneth cell marker *LYZ* should be detected in organoids derived from small intestine (Sato et al. 2011b; Wang et al. 2022b).

Cell composition

Human small intestinal organoids shall contain $LGR5^+$ intestinal stem cells, $KI67^+$ and $LGR5^-$ transit amplifying cells, $ALPI^+$ enterocytes, $MUC2^+$ goblet cells, LYZ^+ Paneth cells and $CHGA^+$ enteroendocrine cells, the percentage of enterocytes shall be no less than 30% (Tetteh et al. 2016; Wang et al. 2020).

Human large intestinal organoids shall contain $LGR5^+$ intestinal stem cells, $KI67^+$ and $LGR5^-$ transit amplifying cells, $ALPI^+$ enterocytes, $MUC2^+$ goblet cells and $CHGA^+$ enteroendocrine cells, the percentage of goblet

cells shall be no less than 30% (Gustafsson and Johansson 2022; Wang et al. 2020).

Functional parameters

Alkaline phosphatase and lysozyme should be detected in human small intestinal organoids (Sensoy and Oznurlu 2019; Wang et al. 2020).

Mucins should be detected in human large intestinal organoids (Chang et al. 1994; Walaas et al. 2023).

Culture and growth

Human intestinal organoids derived from healthy donors shall be able to be passaged for at least 5 generations in vitro after the initial culture, during which the total cell number shall not decrease. Compared to the last generation, the passaged organoids shall have the same morphology, cell composition, karyotype and other characteristics (Sato et al. 2011a).

When organoids are passaged, the cells shall be able to reconstruct into new organoids in vitro, and maintain the capacities of self-renewal and differentiation (Sato et al. 2011a).

Viability

The organoid viability shall be $\geq 50\%$ after thawing, and these living organoids shall be subcultured in vitro.

Microorganisms

Organoids shall be negative for fungi, bacteria, mycoplasma, and virus.

Identity

The identity of organoids shall match that of the donor tissue by STR analysis (Lee et al. 2015).

Test methods

Morphology

Observe organoid morphology by the inverted phase contrast microscope.

Chromosomal karyotype

The method in "Preparation and quality control of animal cells for the production of biological products" from the *Pharmacopoeia of the People's Republic of China* (2020 edition) shall be followed.

Marker genes

The method in Appendix A shall be followed.

Cell composition

The method in Appendix B shall be followed.

Functional parameters

For lysozyme detection, the method in Appendix B shall be followed.

For alkaline phosphatase detection, the method in Appendix C shall be followed.

For mucin detection, the method in Appendix D shall be followed.

Quantity

Count the organoid number, defined by a pre-defined diameter threshold, from the images taken by an inverted phase contrast microscope that is attached with a scale bar.

Viability

Organoid viability testing shall be performed on the primary organoids and passaged organoids, and the method in Appendix E shall be followed.

Microorganisms***Mycoplasma***

The “3301 Mycoplasma Inspection Method” in *Pharmacopoeia of the People’s Republic of China* (2020 edition) shall be followed.

Bacteria and Fungi

The “1101 Sterility Inspection Method” in *Pharmacopoeia of the People’s Republic of China* (2020 edition) shall be followed.

HIV

The method in WS 293 shall be followed.

HBV

The method in WS 299 shall be followed.

HCV

The method in WS 213 shall be followed.

Exogenous viral factors

The “3302 Exogenous Viral Factors Inspection Method” in *Pharmacopoeia of the People’s Republic of China* (2020 edition) shall be followed.

STR

The method in Appendix F shall be followed.

Abbreviations

Ct	Cycle-threshold
DAPI	4,6-Diamino-2-phenyl indole
DMSO	Dimethyl Sulfoxide
HBV	Hepatitis B Virus
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus

PBS	Phosphate Buffer Saline
PCR	Polymerase Chain Reaction
RNA	Ribonucleic Acid
STR	Short Tandem Repeat

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13619-023-00168-5>.

Additional file 1.**Acknowledgements**

We thank Dong Gao, Yi Ariel Zeng, Xia Wang, Xiaolei Yin, Shan Bian, Yongchun Zhang, Yan Liu, Zhiwei Cai, Huili Hu, Lei Chen, Ming Jiang, Ying Xi and Guang Yang for stimulating suggestions.

Authors’ contributions

YGC, GQH, TBZ and AJM contributed to conception and design. YLW, HQL, LZZ and FH drafted and revised the manuscript. JH, ZZ, WQS, LHS, CXD, BZ, JNC, LW (Lei Wang), LW (Liu Wang), LML, WLC, CPY, ZJS, YYY, CLW, YZ, QYL and KL critically read and revised the manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (31988101 to Y.-G.C.; 82173461 To G.Q.H.), Guangdong Basic and Applied Basic Research Foundation (2021A1515111215) to Y.L.W. and China Postdoctoral Science Foundation (2021M703230 and 2022T150653) to Y.L.W., National Key R&D Program of China (2018YFA0108400) to T.B.Z., the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA16040501) to A.J.M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Not applicable.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing financial interests. Y.-G.C. is the Editor-in-Chief of *Cell Regeneration*. He was not involved in the review or decision related to this manuscript. This work was not sponsored by any commercial organizations, and all the other authors declare that they have no competing interests.

Author details

¹The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China. ²Guangzhou Laboratory, Guangzhou 510005, China. ³Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China. ⁴Guangzhou Hua Yi Regeneration Technology Co., Ltd, Huangpu District, Guangzhou 510700, China. ⁵D1 Med Technology (Shanghai) Inc, Shanghai 201802, China. ⁶State Key Laboratory of Stem Cell and Reproductive Biology, Institute for Stem Cell and Regeneration, Institute of Zoology, National Stem Cell Resource Center, Chinese Academy of Sciences, Beijing 100101, China. ⁷Beijing Institute for Stem Cell and Regenerative Medicine, Beijing 100101, China. ⁸University of Chinese Academy of Sciences, Beijing 100049, China. ⁹Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200433, China. ¹⁰Department of Radiation Oncology and Cancer Institute, Fudan University Shanghai Cancer Center Fudan University, Shanghai 200032, China. ¹¹Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. ¹²Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China. ¹³Department

of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. ¹⁴Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu 610072, China. ¹⁵Cancer Centre, Faculty of Health Sciences, University of Macau, Macau 999078, SAR, China. ¹⁶State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China. ¹⁷China Innovation Center of Roche, Li Shi Zhen Road, Pudong, Shanghai 201203, China. ¹⁸Eli Lilly and Company, Pudong, Shanghai 201203, China. ¹⁹K2 Oncology Co., Ltd, KeChuang Street, Beijing 100176, China. ²⁰Qilu Pharmaceutical Co., Ltd, Jinan 250104, China. ²¹China National Institute of Standardization, Beijing 100191, China. ²²Chinese Society for Stem Cell Research, Shanghai 200032, China. ²³HHLIFE Co., Inc, Shenzhen 518040, China. ²⁴China National GeneBank, Shenzhen 518000, China. ²⁵Beijing Technology and Business University, Beijing 100048, China. ²⁶School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.

Published online: 14 June 2023

References

- Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. *Nat Rev Mol Cell Biol.* 2014;15(1):19–33. <https://doi.org/10.1038/nrm3721>.
- Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature.* 2007;449(7165):1003–7. <https://doi.org/10.1038/nature06196>.
- Barker N, van Oudenaarden A, Clevers H. Identifying the stem cell of the intestinal crypt: strategies and pitfalls. *Cell Stem Cell.* 2012;11(4):452–60. <https://doi.org/10.1016/j.stem.2012.09.009>.
- Beumer J, Clevers H. Cell fate specification and differentiation in the adult mammalian intestine. *Nat Rev Mol Cell Biol.* 2021;22(1):39–53. <https://doi.org/10.1038/s41580-020-0278-0>.
- Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. *Nat Rev Microbiol.* 2011;9(5):356–68. <https://doi.org/10.1038/nrmicro2546>.
- Chang SK, Dohrman AF, Basbaum CB, Ho SB, Tsuda T, Toribara NW, et al. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. *Gastroenterology.* 1994;107(1):28–36. [https://doi.org/10.1016/0016-5085\(94\)90057-4](https://doi.org/10.1016/0016-5085(94)90057-4).
- Clevers H. The intestinal crypt, a prototype stem cell compartment. *Cell.* 2013;154(2):274–84. <https://doi.org/10.1016/j.cell.2013.07.004>.
- Clevers H. Modeling Development and Disease with Organoids. *Cell.* 2016;165(7):1586–97. <https://doi.org/10.1016/j.cell.2016.05.082>.
- Fujii M, Sato T. Somatic cell-derived organoids as prototypes of human epithelial tissues and diseases. *Nat Mater.* 2021;20(2):156–69. <https://doi.org/10.1038/s41563-020-0754-0>.
- Ganesh K, Wu C, O'Rourke KP, Szeglin BC, Zheng Y, Sauve CG, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. *Nat Med.* 2019;25(10):1607–14. <https://doi.org/10.1038/s41591-019-0584-2>.
- Gehart H, Clevers H. Tales from the crypt: new insights into intestinal stem cells. *Nat Rev Gastroenterol Hepatol.* 2019;16(1):19–34. <https://doi.org/10.1038/s41575-018-0081-y>.
- Gribble FM, Reimann F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. *Nat Rev Endocrinol.* 2019;15(4):226–37. <https://doi.org/10.1038/s41574-019-0168-8>.
- Gustafsson JK, Johansson MEV. The role of goblet cells and mucus in intestinal homeostasis. *Nat Rev Gastroenterol Hepatol.* 2022;19(12):785–803. <https://doi.org/10.1038/s41575-022-00675-x>.
- Kim J, Koo BK, Knoblich JA. Human organoids: the characteristics of original biology and medicine. *Nat Rev Mol Cell Biol.* 2020;21(10):571–84. <https://doi.org/10.1038/s41580-020-0259-3>.
- Lee SH, Hong JH, Park HK, Park JS, Kim BK, Lee JY, et al. Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors. *Cancer Lett.* 2015;367(1):34–42. <https://doi.org/10.1016/j.canlet.2015.06.024>.
- Porter EM, Bevins CL, Ghosh D, Ganz T. The multifaceted Paneth cell. *Cell Mol Life Sci.* 2002;59(1):156–70. <https://doi.org/10.1007/s00018-002-8412-z>.
- Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. *Science.* 2013;340(6137):1190–4. <https://doi.org/10.1126/science.1234852>.
- Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology.* 2011a;141(5):1762–72. <https://doi.org/10.1053/j.gastro.2011.07.050>.
- Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. *Nature.* 2011b;469(7330):415–8. <https://doi.org/10.1038/nature09637>.
- Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature.* 2009;459(7244):262–5. <https://doi.org/10.1038/nature07935>.
- Sensoy E, Oznuurlu Y. Determination of the changes on the small intestine of pregnant mice by histological, enzyme histochemical, and immunohistochemical methods. *Turk J Gastroenterol.* 2019;30(10):917–24. <https://doi.org/10.5152/tjg.2019.18681>.
- Tetteh PW, Basak O, Farin HF, Wiebrands K, Kretzschmar K, Begthel H, et al. Replacement of Lost Lgr5-Positive Stem Cells through Plasticity of Their Enterocyte-Lineage Daughters. *Cell Stem Cell.* 2016;18(2):203–13. <https://doi.org/10.1016/j.stem.2016.01.001>.
- Walaas GA, Gopalakrishnan S, Bakke I, Skovdahl HK, Flatberg A, Ostvik AE, et al. Physiological hypoxia improves growth and functional differentiation of human intestinal epithelial organoids. *Front Immunol.* 2023;14:1095812. <https://doi.org/10.3389/fimmu.2023.1095812>.
- Wang R, Mao Y, Wang W, Zhou X, Wang W, Gao S, et al. Systematic evaluation of colorectal cancer organoid system by single-cell RNA-Seq analysis. *Genome Biol.* 2022a;23(1):106. <https://doi.org/10.1186/s13059-022-02673-3>.
- Wang Y, Song W, Wang J, Wang T, Xiong X, Qi Z, et al. Single-cell transcriptome analysis reveals differential nutrient absorption functions in human intestine. *J Exp Med.* 2020;217(2). <https://doi.org/10.1084/jem.20191130>.
- Wang Y, Song W, Yu S, Liu Y, Chen YG. Intestinal cellular heterogeneity and disease development revealed by single-cell technology. *Cell Regen.* 2022b;11(1):26. <https://doi.org/10.1186/s13619-022-00127-6>.
- Zeve D, Stas E, de Sousa CJ, Mannam P, Qi W, Yin X, et al. Robust differentiation of human enteroendocrine cells from intestinal stem cells. *Nat Commun.* 2022;13(1):261. <https://doi.org/10.1038/s41467-021-27901-5>.

Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)